

DAFTAR PUSTAKA

1. Kementerian Kesehatan Republik Indonesia. Pedoman nasional pelayanan kedokteran tata laksana kanker payudara. Sustainability (Switzerland). 2019. 1–166 hlm.
2. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, dkk. Current and future burden of breast cancer: global statistics for 2020 and 2040. *The Breast*. 2022;66:15–23.
3. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, dkk. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2024;74(3):229–63.
4. Testa U, Castelli G, Pelosi E. Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments. *Med Sci (Basel)*. 2020;8(18).
5. Breast cancer facts and statistics [Internet]. 2025 [dikutip 23 April 2025]. Tersedia pada: <https://www.breastcancer.org/facts-statistics>
6. Kementerian Kesehatan Republik Indonesia. Laporan tahunan 2022 pencegahan dan pengendalian penyakit tidak menular (PTM). Jakarta; 2022. 1–41 hlm.
7. Damanik DW, Saragih J. Edukasi kesehatan tentang pemeriksaan payudara sendiri (SADARI) sebagai deteksi dini kanker payudara. *Indonesia Berdaya*. 2022;3(1):99–104.
8. Febrianti R, Wahidin M. Hubungan usia dan riwayat keluarga dengan kejadian kanker payudara di Rsup Dr M. Djamil Padang Tahun 2021. *Journal of Scientechnology Research and Development*. 2021;3(1):16–23.
9. Rakha EA, Tse GM, Quinn CM. An update on the pathological classification of breast cancer. *Histopathology*. 2023;82:5–16.
10. Invasive breast carcinoma of no special type and variants Invasive breast cancer of no special type (NST) [Internet]. 2022 [dikutip 29 April 2025]. Tersedia pada: <https://www.pathologyoutlines.com/topic/breastmalignantductalnos.html>
11. Stanisławek A. Breast cancer—Epidemiology, risk factors, classification, prognostic markers, and current treatment strategies— An updated review. *Cancers (Basel)*. 2021;13:1–30.
12. Breast cancer [Internet]. 2024 [dikutip 25 April 2025]. Tersedia pada: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer#:~:text=Overview,producing lobules of the breast>.
13. Smolarz B, Zadrozna Nowak A, Romanowicz H. Breast cancer—Epidemiology, classification, pathogenesis and treatment (Review of Literature). *Cancers (Basel)*. 2022;14:1–27.

14. Akhila G, Nagashree AG N, Spandana KM A, Kumar S H, Harshith HS H, Vardh R V, dkk. An overview of a biomarker in breast cancer. *Int J Pharm Investig*. 2023;13(4):721–34.
15. Finkelman BS, Zhang H, Hicks DG, Turner BM. The evolution of Ki-67 and breast carcinoma: Past observations, present directions, and future considerations. *Cancers (Basel)*. 2023;15.
16. Uxa S, Castillo-Binder P, Kohler R, Stangner K, Müller GA, Engeland K. Ki-67 gene expression. *Cell Death Differ*. 2021;28(12):3357–70.
17. Wongmaneerung P, Chitapanarux I, Traisathit P, Prasitwattanaseree S, Rottuntikarn W, Somwangprasert A, dkk. The association between Ki-67 expression and survival in breast cancer subtypes: a cross-sectional study of Ki-67 cut-point in northern Thailand. *BMC Cancer*. 2025;25(346):1–11.
18. Lee J, Lee YJ, Bae SJ, Baek SH, Kook Y, Cha YJ, dkk. Ki-67, 21-gene recurrence score, endocrine resistance, and survival in patients with breast cancer. *JAMA Netw Open*. 2023;6(8):1–13.
19. Breast cancer grade (nottingham grade) [Internet]. 2023 [dikutip 29 April 2025]. Tersedia pada: <https://www.breastcancer.org/pathology-report/breast-cancer-grades>
20. What's the difference? Grading and staging allow oncologists to home in on a cancer's characteristics [Internet]. 2022 [dikutip 29 April 2025]. Tersedia pada: <https://www.cancercenter.com/community/blog/2022/08/staging-vs-grading-cancer>
21. Ibrahim A, Lashen A, Toss M, Mihai R, Rakha E. Assessment of mitotic activity in breast cancer: revisited in the digital pathology era. *J Clin Pathol*. 2022;75:365–72.
22. Lashen AG, Toss MS, Katayama A, Mongan NP, Rakha EA. Assessment of proliferation in breast cancer : cell cycle or mitosis ? An observational study. *Histopathology*. 2021;79:1087–98.
23. Hacking SM, Wang Y. Practical issues of Ki-67 evaluation in breast cancer clinical practice. *Journal of Clinical and Translational Pathology* [Internet]. 2022;2(2):53–6.
24. Putri DAR, Raharjo EN, Azahra S. Korelasi ekspresi Ki-67 dan indeks mitosis pasien kanker payudara di RSUD AWS. *Jurnal Ilmu Kesehatan*. 2023;7(1):54–9.
25. Huang W, Nebiolo C, Esbona K, Hu R, Lloyd R. Ki67 index and mitotic count: Correlation and variables affecting the accuracy of the quantification in endocrine/neuroendocrine tumors. *Ann Diagn Pathol* [Internet]. 2020;48:151586.
26. Bazira PJ, Ellis H, Mahadevan V. Anatomy and physiology of the breast. *Surgery* [Internet]. 2021;40(2):79–83.

27. Barbara L. Hoffman M, John O. Schorge M, Karen D. Bradshaw M, Lisa M. Halvorson M, Joseph I. Schaffer M, Marlene M. Corton M. Williams gynecology. Sustainability (Switzerland). 2019. 1–14 hlm.
28. Anatomy [Internet]. 2025 [dikutip 27 April 2025]. Tersedia pada: <https://training.seer.cancer.gov/breast/anatomy.html>
29. Of journal “Morphologia” E office. Junqueira’s basic histology : text & atlas. Morphologia. 2019. 101–104 hlm.
30. Adolph R. diFiore’s atlas of histology. 2016. 1–23 hlm.
31. What is breast cancer? [Internet]. 2021 [dikutip 25 April 2025]. Tersedia pada: <https://www.cancer.org/cancer/types/breast-cancer/about/what-is-breast-cancer.html>
32. Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, dkk. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74(6):477–95.
33. Hero SK. Faktor risiko kanker payudara. Jurnal Medika Utama. 2021;03(01):1533–8.
34. Review N, Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024;103(3):1–6.
35. Youn HJ, Han W. A review of the epidemiology of breast cancer in Asia : Focus on risk factors. Asian Pacific Journal of Cancer Prevention. 2020;21(4):867–80.
36. Roheel A, Khan A, Anwar F, Akbar Z, Akhtar MF, Imran Khan M, dkk. Global epidemiology of breast cancer based on risk factors: a systematic review. Front Oncol. 2023;13.
37. Jurdana M. Physical activity and cancer risk. Actual knowledge and possible biological mechanisms. Vol. 55, Radiology and Oncology. 2021. hlm. 7–17.
38. Xiong X, Zheng L wei, Ding Y, Chen Y fei, Cai Y wen, Wang L ping, dkk. Breast cancer : pathogenesis and treatments. Signal Transduct Target Ther. 2025;49(10):1–33.
39. Carcinogenesis [Internet]. 2024 [dikutip 12 Oktober 2025]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK604463/>
40. Lasek W. Cancer immunoediting hypothesis: history, clinical implications and controversies. Central European Journal of Immunology. 2022;47(2):168–74.
41. van Dooijeweert C, van Diest PJ, Ellis IO. Grading of invasive breast carcinoma: the way forward. Virchows Archiv. 2022;480:33–43.
42. Tan XJ, Cheor WL, Cheng EM, Ab Rahman KS, Wan Muhamad WZA, Leow WZ. Breast cancer status, grading system, etiology, and challenges in Asia: An updated review. Oncologie. 2023;25(2):99–110.

43. Sun Z hong, Chen C, Kuang X wen, Song J long, Sun S rong, Wang W xing. Breast surgery for young women with early-stage breast cancer. *Medicine*. 2021;100(18):1–10.
44. Korde LA, Somer MR, Carey LA, Crews JR, Denduluri N. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer : ASCO guideline abstract. *american society of clinical oncology*. 2021;39(13):1485–505.
45. Ma Q, Liu YB, She T, Liu XL. The role of Ki-67 in HR+/HER2-breast cancer: A real-world study of 956 patients. *Breast Cancer: Targets and Therapy*. 2024;16:117–26.
46. Probert J, Dodwell D, Broggio J, Charman J, Dowsett M, Kerr A, dkk. Ki67 and breast cancer mortality in women with invasive breast cancer. *JNCI Cancer Spectr*. 2023;7(5):1–10.
47. Invasive breast cancer (no special type) [Internet]. 2025 [dikutip 8 Mei 2025]. Tersedia pada: <https://breastcancernow.org/about-breast-cancer/diagnosis/types-of-breast-cancer/invasive-breast-cancer-no-special-type>
48. Surabhi DM, Wilson JC, Singh M, Green L. Recognizing invasive breast carcinoma of no special type with medullary pattern. *Radiol Case Rep*. 2023;18:1788–92.
49. Skandhan A, Niknejad MT, Yap J. Invasive breast carcinoma of no special type. Dalam *Radiopaedia.org*; 2014.
50. Sereda EE, Kolegova ElenaS, Kakurina G V., Korshunov DA, Sidenko EA, Doroshenko A V., dkk. Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes. *Translational Breast Cancer Research*. 2022;3(23):1–13.
51. Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, dkk. Assessment of Ki67 in breast cancer: Updated recommendations from the international Ki67 in breast cancer working group. *J Natl Cancer Inst*. 2021;113(7):808–19.
52. Liu Y, Li X, Zheng A, Zhu X, Liu S, Hu M, dkk. Predict Ki-67 positive cells in H&E-stained images using deep learning independently from IHC-stained images. *Front Mol Biosci*. 2020;7:1–10.
53. Shim VC, Baker RJ, Jing W, Puentes R, Agersborg SS, Lee TK, dkk. Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system. *Breast Cancer Res Treat*. 2024;203:281–9.
54. Choi SB, Park JM, Ahn JH, Go J, Kim J, Park HS, dkk. Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen? *Breast Cancer Res Treat*. 2022;192:343–52.

55. Polewski MD, Nielsen GB, Gu Y, Weaver AT, Gegg G, Tabuena-Frolli S, dkk. A standardized investigational Ki-67 immunohistochemistry assay used to assess high-risk early breast cancer patients in the monarchE phase 3 clinical study identifies a population with greater risk of disease recurrence when treated with endocrine therapy alone. *Applied Immunohistochemistry and Molecular Morphology*. 2022;30(4):237–45.
56. Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. *Cancers (Basel)*. 2021;13:1–19.
57. Thomssen C, Balic M, Harbeck N, Gnant M. St. Gallen/Vienna 2021: A brief summary of the consensus discussion on customizing therapies for women with early breast cancer. Vol. 16, *Breast Care*. S. Karger AG; 2021. hlm. 135–43.
58. Lashen A, Toss MS, Alsaleem M, Green AR, Mongan NP. The characteristics and clinical significance of atypical mitosis in breast cancer. *Modern Pathology*. 2022;35:1341–8.
59. Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, dkk. The 2019 World Health Organization classification of tumours of the breast. *Histopathology*. 2020;77:181–5.
60. Ellis IO, Rakha EA, Tse GM, Tan PH. An international unified approach to reporting and grading invasive breast cancer. An overview of the International Collaboration on Cancer Reporting (ICCR) initiative. Vol. 82, *Histopathology*. John Wiley and Sons Inc; 2023. hlm. 189–97.
61. Dahlan MS. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. Jakarta; 2016. 1–23 hlm.
62. Muh Farhan I, Syahril E, Chalid A, Irwan Gunawan M, Paulina Christina L. Evaluasi kejadian kanker payudara di RS Ibnu Sina Kota Makassar Tahun 2024. 2025;5(1):14–21.
63. WHO Classification of Tumours Editorial Board. Breast tumour. Vol. 2. Lyon, France: International Agency for Research on Cancer; 2019.
64. Reproductive factors [Internet]. 2024 [dikutip 22 Oktober 2025]. Tersedia pada: <https://www.canceraustralia.gov.au/breast-cancer-risk-factors/risk-factors/reproductive-factors>
65. Rajaneesh N, Venkatesh S. Lifestyle Modifications and Genetic Factors Affecting Breast Cancer Review Article. 2023;1(1):8–14.
66. Sandilya U, K M. Expression of Ki-67 in invasive breast carcinoma and its correlation with different clinicopathological features. *Cureus*. 2024;16(9):1–14.
67. Belachew EB, Desta AF, Deneke DB, Fenta BD, Alem AT, Abafogi AK, dkk. Clinicopathological features of invasive breast cancer: A five-year

- retrospective study in Southern and South-Western Ethiopia. *Medicines*. 2023;10(30):1–10.
68. García-Sancha N, Corchado-Cobos R, Pérez-Losada J. Understanding susceptibility to breast cancer: from risk factors to prevention strategies. *Int J Mol Sci*. 2025;26:1–32.
 69. Kim J, Munster PN. Estrogens and breast cancer. *Annals of Oncology*. 2025;36(2):134–48.
 70. Altundag K, Kupik G, Kupik O. Clinical and histopathological characteristics of male breast cancer: A single center experience. *JBUON*. 2021;26(6):2292–7.
 71. Az Zahra J, Santosa A, Do Toka W. Karakteristik klinikopatologi karsinoma duktal invasif di Maluku Utara. *Malahayati Nursing Journal*. 2024;6(9):3753–64.
 72. Varzaru VB, Anastasiu-Popov DM, Eftenoiu AE, Popescu R, Vlad DC, Vlad CS, dkk. Observational study of men and women with breast cancer in terms of overall survival. *Cancers (Basel)*. 2024;16:1–11.
 73. American Cancer Society. Breast cancer facts and figures 2024-2025. American Cancer Society. 2024;1–25.
 74. Campos FAB, Rouleau E, Torrezan GT, Carraro DM, Casali da Rocha JC, Mantovani HK, dkk. Genetic landscape of male breast cancer. *Cancers (Basel)*. 2021;13:1–24.
 75. Zheng G, Leone JP. Male breast cancer: an updated review of epidemiology, clinicopathology, and treatment. *J Oncol*. 2022;2022:1–11.
 76. Clusan L, Ferrière F, Flouriot G, Pakdel F. A basic review on estrogen receptor signaling pathways in breast cancer. Vol. 24, *International Journal of Molecular Sciences*. Multidisciplinary Digital Publishing Institute (MDP); 2023. hlm. 1–19.
 77. Breast Cancer Surgery [Internet]. 2023 [dikutip 25 Oktober 2025]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK553076/>
 78. Flindris S, Margioulas-Siarkou C, Margioulas-Siarkou G, Markozannes G, Empliouk E, Tasiou D, dkk. Breast cancer surgery at a tertiary center in greece: clinicopathological associations and patient outcomes. *Cureus*. 2025;17(7):1–10.
 79. Tong Y, Sun F, Zhang C, Yang S, Yu Z, Zhao Y. Multifocal/multicentric breast cancer: does each focus matter? *Cancer Med*. 2023;12:8815–24.
 80. Gentile D, Martorana F, Karakatsanis A, Caruso F, Caruso M, Castiglione G, dkk. Predictors of mastectomy in breast cancer patients with complete remission of primary tumor after neoadjuvant therapy: a retrospective study. *European Journal of Surgical Oncology*. 2024;50:1–7.

81. Teng R, Wei Q, Zhou J, Dong M, Jin L, Hu W, dkk. The influence of preoperative biopsy on the surgical method in breast cancer patients: a single-center experience of 3,966 cases in China. *Gland Surg.* 2021;10(3):1038–45.
82. Andrés-Sánchez N, Fisher D, Krasinska L. Physiological functions and roles in cancer of the proliferation marker Ki-67. Vol. 135, *Journal of Cell Science*. Company of Biologists Ltd; 2022. hlm. 1–13.
83. Maranta AF, Broder S, Fritzsche C, Knauer M, Thürlimann B, Jochum W, dkk. Do you know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. *Breast.* 2020;51:120–6.
84. Rais G, Mokfi R, Boutaggount F, Maskrout M, Bennour S, Senoussi C, dkk. Assessment of the predictive role of Ki-67 in breast cancer patients' responses to neoadjuvant chemotherapy. *Eur J Breast Health.* 2024;20(3):199–206.
85. Genetics, cancer cell cycle phases [Internet]. 2023 [dikutip 12 Oktober 2025]. Tersedia pada: <https://www.ncbi.nlm.nih.gov/books/NBK563158/>
86. Korpinen K, Autere TA, Tuominen J, Löyttyniemi E, Eigeliene N, Talvinen K, dkk. Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma. *Breast Cancer Res Treat.* 2025;210(2):463–75.

